These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 2526109)

  • 21. [Clinical study of teicoplanin in the treatment of patients with gram-positive cocci: the Chinese experience].
    He LX; Pan J; Chen SY; Wang AX; Xie CM; Shen ZY
    Zhonghua Nei Ke Za Zhi; 2005 May; 44(5):337-41. PubMed ID: 16009001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Teicoplanin in the treatment of skin and soft tissue infections: results of a multicentre study.
    Lang E; Földes M; Marghescu S
    Infection; 1991; 19(3):190-4. PubMed ID: 1832418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
    Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
    Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Teicoplanin in infections caused by methicillin-resistant staphylococci.
    Drabu YJ; Walsh B; Blakemore PH; Mehtar S
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():89-92. PubMed ID: 2965136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of serious staphylococcal infections in the outpatient setting.
    Graninger W; Presterl E; Wenisch C; Schwameis E; Breyer S; Vukovich T
    Drugs; 1997; 54 Suppl 6():21-8. PubMed ID: 9474478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teicoplanin for therapy of gram-positive infections in neutropenic patients.
    Verhagen C; De Pauw BE
    Int J Clin Pharmacol Res; 1987; 7(6):491-8. PubMed ID: 2964418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Campoli-Richards DM; Brogden RN; Faulds D
    Drugs; 1990 Sep; 40(3):449-86. PubMed ID: 2146108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Teicoplanin, a new antibiotic effective against gram-positive bacterial infections of the skin and soft tissues.
    Bochud-Gabellon I; Regamey C
    Dermatologica; 1988; 176(1):29-38. PubMed ID: 2962889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Teicoplanin in the treatment of infections caused by coagulase-negative staphylococci.
    Harding I; Garaud JJ
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():93-103. PubMed ID: 2965137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro susceptibility of Staphylococci and Enterococci to vancomycin and teicoplanin.
    Guzek A; Korzeniewski K; Nitsch-Osuch A; Rybicki Z; Prokop E
    Adv Exp Med Biol; 2013; 788():125-32. PubMed ID: 23835969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of a glycopeptide antibiotic, teicoplanin, in the treatment of septicaemia caused by gram-positive bacteria.
    Webster A; Wilson AP; Treasure T; Grüneberg RN
    Int J Clin Pharmacol Res; 1988; 8(2):95-8. PubMed ID: 2967800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The use of teicoplanin in neutropenic patients: values and limits].
    Espinouse D; Chomarat M
    Pathol Biol (Paris); 1990 Jun; 38(5 ( Pt 2)):552-6. PubMed ID: 2143573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and pharmacodynamics of teicoplanin given daily during the first 3 days and then on alternate days for methicillin-resistant Staphylococcus aureus infections.
    Bantar C; Durlach R; Nicola F; Freuler C; Bonvehí P; Vazquez R; Smayevsky J
    J Antimicrob Chemother; 1999 May; 43(5):737-40. PubMed ID: 10382901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open study of teicoplanin in the treatment of gram-positive infections.
    Nathwani D; Reid TM; Gould IM; Golder D; Smith CC; Douglas JG
    J Chemother; 1991 Oct; 3(5):315-20. PubMed ID: 1839742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycopeptides in the treatment of staphylococcal infections.
    Daschner FD; Kropec A
    Eur J Clin Microbiol Infect Dis; 1995; 14 Suppl 1():S12-7. PubMed ID: 7729466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin.
    Greenberg RN
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2392-7. PubMed ID: 2150908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy and safety of teicoplanin in the treatment of gram-positive infections.
    Kempf P; Pompetzki H; Oppermann A; Wittenberger R; Siebert J; Fell JJ; Dieterich HA
    Infection; 1989; 17(3):177-81. PubMed ID: 2525529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
    Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A
    Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration.
    Peeters O; Ferry T; Ader F; Boibieux A; Braun E; Bouaziz A; Karsenty J; Forestier E; Laurent F; Lustig S; Chidiac C; Valour F;
    BMC Infect Dis; 2016 Nov; 16(1):622. PubMed ID: 27809799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.